Covid-19 living Data

COVID-19 vaccine effectiveness
(Randomized evidence)

Analyses are updated every Friday

Variants of concern

Treatment comparisons

Trial	Type	Comparisons		Design	Participants	Sample size	Overall risk of bias Highest assessment	Full description
		Intervention 1	Intervention 2
NCT04470427 ModernaTX Baden LR, N Engl J Med, 2020 COVE Full text Commentary	RNA based vaccine	mRNA-1273	Placebo	RCT Phase 3	Healthy adults with no known history of SARS-CoV-2 infection in 99 centers in the US	N=30420	Some concerns Details	Full description
NCT04860739, EudraCT2021-001978-37 Pfizer/BioNTech + Fosun Pharma Borobia A M, Lancet, 2021 Full text Commentary	RNA based vaccine	BNT162b2	No vaccine	RCT Phase 2	Healthy, or clinically stable, adults (aged ≥18 and ≤60) that were SARS-COV-2 infection free and who had received a prime ChAdOx1-S vaccination between 8 and 12 weeks before the screening visit in 5 centers in Spain.	N=676	Some concerns Details	Full description
NCT04368728 Pfizer/BioNTech + Fosun Pharma Frenck R, N Engl J Med, 2021 Full text Commentary	RNA based vaccine	BNT162b2	Placebo	RCT Phase 3	Adolescents aged 12 to 15 years with no previous Covid-19 diagnosis or SARS-CoV-2 infection in 29 centers in the USA	N=2264	Some concerns Details	Full description
ChiCTR2000034825 ; NCT04523571 BioNTech RNA Pharmaceuticals Li J, Nature Medicine, 2021 Full text Commentary	RNA based vaccine	BNT162b1 10 mcg	BNT162b1 10 mcg	RCT Phase 1	Healthy young adults between 18 and 55 years of age, and older adults between 65 and 85 that were SARS-COVID-2 infection-free at a single center in China.	N=144	Low Details	Full description
ISRCTN69254139, EudraCT: 2020-005085-33 AstraZeneca+University of Oxford; Pfizer/BioNTech+Fosun Pharma Liu X, SSRN, 2021 Com-COV Full text Commentary Commentary Commentary Commentary	RNA based vaccine	ChAd/ChAd-28 BNT/BNT-28	ChAd/BNT-28 BNT/ChAd-28	RCT Phase 2	Adults 50 years or older with no previous SARS-CoV-2 infection, no or well-controlled mild-moderate comorbidities and HIV-negative in 8 centers in the UK	N=463	Some concerns Details	Full description
NCT04368728 Pfizer/BioNTech + Fosun Pharma Polack F, N Engl J Med, 2020 Full text Commentary ; Commentary ; Commentary ; Commentary ; Commentary	RNA based vaccine	BNT162b2	Placebo	RCT Phase 2/3	Healthy SARS-CoV-2 DNA negative adults in multiple centres in Argentina, Brazil, Germany, South Africa, Turkey, and the USA	N=43448	Some concerns Details	Full description
NCT04368728 BioNTech SE, Pfizer Walsh E, N Engl J Med, 2020 Full text Commentary	RNA based vaccine	BNT162b1 10 mcg D1/21 BNT162b1 20 mcg D1/21 BNT162b1 30 mcg D1/21 BNT162b1 100 mcg D1/21 BNT162b2 10 mcg D1/21 BNT162b2 20 mcg D1/21 BNT162b2 30 mcg D1/21	BNT162b1 30 mcg D1/21	RCT Phase 1	Healthy SARS-CoV-2 serology/DNA negative adults in four centres in USA	N=195	Low Details	Full description
NCT04523571 ; ChiCTR BioNTech / Pfizer / Fosun Pharma Zhu F, ResearchSquare, 2021 Full text Commentary ; Commentary	RNA based vaccine	BNT126b1 10 mcg/0.5 ml 2- BNT126b1 30 mcg/0.5 ml 2-	Placebo	RCT Phase 1	Healthy SARS-CoV-2 infection-free adults aged 18-55 and 65-85 at a single center in China	N=144	Some concerns Details	Full description